Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing
· seekingalpha.com
REGENXBIO expects to resubmit NAVSUNLI BLA in Q3 2026, leveraging robust CAMPSIITE trial data. Read why RGNX stock is a Strong Buy.
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...